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Abstract
Background/Objective: Bladder cancer is the commonest type of malignant tumors as a result of schistosomaisis
which is a major healthy problem in many subtropical developing countries. The aim of this study is to
comparatively elucidate the underlying biochemical tumor markers in schistosomal bladder cancer versus non-
schistosomal bladder cancer when compared to normal healthy ones.
Methods: This work was performed on tissue specimens from total 25 patients and serum samples from total 30
patients versus ten healthy individuals served as control. The investigated parameters in serum are: xanthine
oxidase (XO), fructosamine, lactate dehydrogense (LDH), aspartate aminotransferase (AST), alanine aminotransferase
(ALT), total proteins, essential and non- essential amino acids profile, hydroxyproline, total immunoglobulin E (IgE)
and tumor necrosis factor alpha (TNF-a). In addition, the current investigation also extended to study some
markers in tumor bladder tissues including, pyruvate kinase enzyme (PK), lactate dehydrogenase (LDH), aspartate
aminotransferase (AST) and alanine aminotransferase (ALT).
Results: Results showed that biharzial bladder cancer patients recored more significant elevation in serum XO,
fructosamine, LDH, AST, ALT, hydroxyproline, IgE and TNF-a than in bladder cancer patients when compared to
control ones. While, in tissues there were significant increase in PK, LDH, AST & ALT activities of schistosomal
bladder cancer than in bladder cancer as compared to control healthy patients.
Conclusions: It could be concluded that, bilharzial and non-bilharzial bladder cancer showed distinct biochemical
profile of tumor development and progression which can be taken into consideration in diagnosis of bladder
cancer.
1. Introduction
Bladder cancer is the second most common malignancy
of the genitourinary system in males and females [1,2],
accounting for 6% to 8% of all male malignancies and
2% to 3% of all female malignancies [3]. In Africa, squa-
mous cell carcinoma of the bladder is greatly overrepre-
sented among the fellaheen (peasant farmers) of Egypt
and the Africans of Mozambique, Zimbabwe, and Zam-
bia (formerly Rhodesia), all countries where Schistosoma
haematobium is endemic. An age-standardized mortality
rate for bladder cancer of 10.8 per 100,000 males places
Egypt at the top of the list of the 54 countries providing
data for the 1987 WHO database [4].
The most common type diagnosed in North and
South America, Europe and Asia is transitional cell car-
cinoma, which is mainly non-schistosomal bladder
tumors, followed by squamous cell carcinoma which is
found more in geographical regions where schistosomia-
sis is prevalent [1]. One of the conditions leads to blad-
der cancer in Africa, the Middle East and Asia is
schistosomiasis [5]. Schistosoma haematobium is the
most predominant species in the Middle East, Asia, and
Africa, and the most implicated in the schistosomal
bladder tumors in these regions [6].
No prospective study measuring the risk of developing
bladder cancer in infected and uninfected persons is yet
available. Although differences in relative frequencies
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tors, such as geopolitical variations in case finding, can
result in spurious differences and erroneous associa-
tions. If the postulated association is correct, one of sev-
eral conditions must obtain: the worm (1) produces a
carcinogen, (2) carries a virus, or (3) is cocarcinogenic
to some other insult. In this case, there are many unan-
swered questions regarding geographic differences in
vesical cancer observed where schistosomiasis is ende-
mic. These range from whether there is geographic uni-
formity in the host’s reaction to infection to whether
other environmental variables (such as the bright food
coloring used in the candy popular in the Nile delta)
interact and are additionally responsible for vesical neo-
plasia [7].
T h e r ei ss o m ee v i d e n c es u g g e s t i n gt h a to x i d a t i v e
stress and bladder cancer are closely related [8,9]. Inher-
ent oxidative stress may affect several functions in can-
cer cells or tumor tissue such as cell proliferation,
promotion of mutations and genetic instability, altera-
tions in cellular sensitivity to anticancer agents, invasion,
and metastasis [10]. Hydroxyl radicals, peroxides and
superoxides are reactive oxygen species (ROS) that are
generated during everyday metabolic processes in a nor-
mal cell. ROS generated either endogenously (mitochon-
dria, metabolic process, inflammation etc.) or from
external sources play a vital role in regulating several
biologic phenomena [11]. While increased ROS genera-
tion has traditionally been associated with tissue injury
or damage of many different biomolecules including
DNA, proteins, lipids and carbohydrates which are gen-
eral manifestations of pathological conditions associated
with infection, aging, mitochondrial DNA mutations and
cellular proliferation [12-14]. Thus, excessive production
of ROS or inadequacy in a normal cell’s anti-oxidant
defense system (or both) can cause the cell to experi-
ence oxidative stress and the increased ROS may play a
broader role in cellular process associated with initiation
and development of cancers [15]. In view of the above
information, the objective of this study was undertaken
t oi n v e s t i g a t es o m ek e yf i n d ings relevant to ROS stress
in bilharzial and non bilharzial bladder cancer compared
to control healthy patients. The investigated parameters
in serum including xanthine oxidase (XO) enzyme activ-
ity (as a marker of purine metabolism), fructosamine (as
a marker of abnormal glucose metabolism), lactate dehy-
drogenase (as a maker of glucose metabolism), hydroxyl-
proline (as a maker of liver fibrosis), as well as total
serum immunoglobulin E (IgE), tumor necrosis factor-
alpha (TNF-a) and liver function enzymes including
aspartate and alanine aminotransferase (AST & ALT),
total proteins and free amino acids were also measured
in serum. The study was extended to investigate some
biochemical parameters in tumor tissues isolated from
bladder carcinoma patients including, pyruvate kinase
(PK), AST, ALT and LDH enzymes.
2. Materials and methods
2.1 Clinical cases
All cases (55 individuals) were of Egyptian bladder carci-
noma patients, attending to out clinic, Medicine Oncol-
ogy and Pathology Departments - National Cancer
Institute - Cairo University.
This work was performed on tissue specimens from
total 25 patients and serum samples from total 30
patients. The patients were classified according to the
clinical and pathological receptors into two subdivisions:
1. Having malignant carcinoma patients.
2. Having bilharzial bladder lesions.
Diagnoses were confirmed by microscopic studies,
where the bladder cancer was sequamous cell carcinoma
(SCC).
The tumors isolated surgically from a total of 25 indi-
viduals and divided into: 1) first group consists of 12
patients with bladder carcinoma [11 male, their ages
ranged from 16-58 years and 1 female has 32 years old].
2) Second group consists of 13 subjects having schisto-
somale infection [9 males, their ages ranged from 21-68
and 4 females, ranged from 34-59 years old].
The serum analysis was conducted on 30 patients, 15
bladder carcinoma [10 males (17-61 years old) and 5
females (26-39 years old] and 15 bilharzial bladder carci-
noma [12 males (20-63 years old) and 3 females (18-35
years old)].
2.2. Control group
1. serum: ten healthy individuals were served as controls
to all investigated serum groups.
2. tissue samples: The activities were measured in
nighboring mucosa (unaffected tissues) to carcinoma tis-
sues together with bilharzias bladder carcinoma tissues.
2.3. Gross Pathology
Tissue samples of bladder carcinoma, were subjected to
both pathological and histological examinations in order
to evaluate the criteria of diagnosis and diseases progress,
at pathology department, NCI. The original cell micro-
scopic slid were examined and the tumors were classified
as squamous carcinoma which included grade I × II and
adenocarcinoma cells including grade three (III).
2.4. Parameters Assays
For Serum tests
Serum was separated by centrifugation at 3000 rpm and
subjected to the following biochemical tests: XO activity
was determined by the reduction of nitro-blue tetrazo-
lium (NBT) in the presence of xanthine, forming forma-
zan. The enzyme activity was calculated using the
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2/μmol at
540 nm) [16]. Fructosamine was determined according
to the method of Parlin et al., [17] where fructosamine
reduces NBT under alkaline condition and forms a pur-
ple-colored formazan with an absorption maximum at
530 nm. LDH was detected in serum using Beckman
LDH kit. ASTand ALT were estimated using Stanbio kit
produced by Stanbio Labs, Texas, USA. A total protein
was determined by using the method of Lowry et al.
[18]. Hydroxyproline content was measured using the
method of Jamall et al. [19]. The level of total IgE was
measured by ELISA at 450 nm and compared with
known mouse IgE standard (BD PharMingen). TNF-a
was quantified using a commercial ELISA kit (Endogen,
Woburn, MA). The amino acids constituents of patient
serum were determined using HPLC.Eppdrof -Germany-
Lc3000 amino acid analyzer.
2.5. For tumors tissues
The tissues were free of necrotic debris, connective tis-
sues and were immediately frozen after surgrey. Mea-
surement of ASTand ALT activities in tumors tissue
homogenates were carried out by colorimetric technique
of Nabih et al. [20]. While LDH activity was assayed in
the same homogenate by the method of Caboud and
Wroblewski [21]. Pyruvatek i n a s ew a sd e t e r m i n e db y
using the method of Ibsen et al. [22].
2.6. Statistical analysis
All data obtained are expressed as the mean ± SD.
R e s u l t sw e r ea n a l y z e db yac o m p u t e r i z e ds t a t i s t i c a lp r o -
gram. Values were compared by one-way ANOVA for
multiple comparisons as the post hoc test. A P-value <
0.05 was considered to be statistically significant.
3. Results
Table (1) shows significant increase in serum XO
enzyme activity, fructosamine, hydroxyproline, IgE, and
TNF- a concentrations in bilharzial bladder cancer
patients compared to non- bilharzial bladder cancer
ones and control healthy patients. While data in Table
(2) shows significant increase in serum enzymes includ-
ing AST, ALT and LDH in both diseased patients
groups compared to healthy cases. The results of total
proteins reveals a moderate increase in bilharzial blad-
der patients as compared to control cases, but there is a
non- significant decrease in total proteins in bladder
cases compared to normal persons as shown in table
(2). Table (3) shows highly significant increase in LDH,
AST, ALT, and pyruvate kinase activities in both bilhar-
zial and non bilharzial bladder cancer patients and the
highest increase was observed in patients of grade three
compared to healthy ones.
From our study, It is clear that all total amino acid
levels significantly increased in bladder cancer patient
with different percentage change except a-aminoadipic
acid with -99.9%, glycine -35%, cystathionine -83.42%,
tryptophan with -66% and carnosine with -41%. In bil-
harzial bladder cancer, Taurine, a-Aminoadipic acid,
Glycine, a-Aminobutyric acid and Cystathionine were
reduced with 8.06, 81.57, 94.92 and 49.0% respectively,
while the other amino acids were elevated (tables 4,5).
4. Discussion
Oxidative stress induces a cellular redox imbalance that
has been found to be present in various cancer cells as
compared with normal cells, the redox imbalance thus
may be related to oncogenic stimulation [23]. The dis-
turbance of the pro-oxidant/antioxidant balance, result-
ing from increased free radical production, antioxidant
enzyme inactivation, and excessive antioxidant con-
sumption, is the causative factor in oxidative damage
[24]. There are potentially different types of DNA
lesions resulting from ROS and reactive nitrogen spe-
cies, which could be mutagenic and involved in the
etiology of cancer [25].
Table 1 Serum tumor markers in bilharzial and non-bilharzial bladder cancer patients compared to normal
(unaffected) patients
Parameters Control Bilharzial bladder
cancer patients
non-bilharzial
bladder cancer
patients
ANOVA
P<
1. XO (μmol uric acid/min/ml)
LSD
0.3 ± 0.05
(2,3)
2.77 ± 0.33
(1,3)
1.58 ± 0.23
(1,2)
P < 0.0001
2. Fructosamine (μmol/L)
LSD
337.88 ± 34.4
(2,3)
1145.27 ± 146.16
(1,3)
742.3 ± 132.44
(1,2)
P < 0.0001
3. hydroxylproline (μg/ml)
LSD
23.35 ± 2.83
(2,3)
78.56 ± 10.48
(1,3)
46.06 ± 4.28
(1,2)
P < 0.0001
4. IgE (IU/ml)
LSD
44.37 ± 1.66
(2,3)
301.49 ± 14.04
(1,3)
269.0 ± 7.66
(1,2)
P < 0.0001
5. TNF-∝ (Pg/ml)
LSD
7.8 ± 0.22
(2,3)
37.7 ± 1.61
(1,3)
24.6 ± 0.84
(1,2)
P < 0.0001
Data are represented as mean ± SD of 10 control and 30 patients (15 patients bilharzial and 15 non-bilharzial)
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ing a part in purine metabolism. It catalyzes the conver-
sion reactions of hypoxanthine to xanthine and
xanthine to uric acid, the last reaction in the purine cat-
abolism, with byproduct of toxic superoxide radical. In
this regard, it is a key enzyme between purine and free
radical metabolism. It was reported that XO is an endo-
genous source of ROS and reactive nitrogen species
(RNS) that can induce oxidative stress and inflect tissue
injury [26,27]. There is growing evidence that superox-
ide radicals generated by XO are primarily responsible
for the cellular deterioration associated with several
conditions [28].
The data reported in the literature on oxidant, antiox-
idant molecule, and enzymes in different human cancer
types are controversial. Our findings show significant
increase in XO activity of bilharzial bladder cancer and
non-bilharzial bladder cancer patients compared to
normal healthy ones. Kokoglu et al. [29] found higher
XO activity in tumoral brain tissues and suggested that
the levels of XO in brain tissues could be used as a bio-
chemical marker for the differentiation of tumoral tis-
sues from normal ones. Our findings are consistent
with Kaynar et al. [30] who found an increase in XO
activity in patients with small cell and non-small cell
lung cancer. Also, Ozturk et al. [31] observed a signifi-
cant increase in XO activity in patients with colorectal
cancer compared to control group. The authors attribu-
ted this increase in this enzyme to an unbalancement
alteration in oxidant-antioxidant status due to the can-
cer process. In addition, Gülec et al. [28] found that XO
activity increased in bladder cancer patients suggested
that oxidative stress might be increased in cancerous
changes and process, and may affect the course of the
disease. The burst of XO-mediated free oxygen radical
generation in the cancerous tissue can be triggered by a
Table 2 Serum enzymes in bilharzial and non-bilharzial bladder cancerous patients in comparison to healthy persons
Parameters Grading progress Healthy cases Bilharzial bladder cancerous patients non-bilharzial bladder cancerous patients
I II III I II III
n=1 0 n=4 n=5 n=6 n=6 n=4 n=5
AST (U/L) Mean ± S.D 28.4 ± 2.3 102.7 ± 6.9 120.6 ± 8.5 132.9 ± 10.1 85.3 ± 4.9 96.5 ± 9.3 107.3 ± 11.6
P< – H.S H.S H.S H.S H.S H.S
ALT (U/L) Mean ± S.D 26.3 ± 1.8 82.2 ± 3.95 96.5 ± 6.1 111.1 ± 9.9 69.3 ± 6.5 83.3 ± 7.6 99.8 ± 6.7
P< – H.S H.S H.S H.S H.S H.S
LDH (U/L) Mean ± S.D 139.9 ± 13.8 351.5 ± 20.2 434.7 ± 21.4 489.3 ± 37.6 334.4 ± 15.5 379.1 ± 14.2 408.6 ± 14.2
P< – H.S H.S H.S H.S H.S H.S
Total protein gm% Mean ± S.D 7.7 ± 0.5 8.30 ± 0.6 8.40 ± 0.4 9.30 ± 0.3 7.40 ± 0.3 7.5 ± 0.4 7.80 + 0.5
P< – S S S N.S N.S N.S
H.S: P < 0.0005 N.S: P < 0.02
Table 3 Tumor marker enzymes in bilharzial and non-bilharzial carcinoma tissues compared to normal (unaffected)
tissues
Enzymes Tissues
types
Bilharzial bladder cancerous tissues n = 13 Bladder cancerous tissues n = 12
Unaffected (normal) tissues Malignant tissues Unaffected (normal) tissues Malignant tissues
Grading I II III I II III I II III I II III
LDH Mean ± SD 8.5 ±
0.33
8.8 ±
0.21
9.1 ±
0.12
15.4 ±
0.2
16.3 ±
0.21
17.3 ±
0.17
6.1 ±
0.14
6.9 ±
0.24
7.2 ±
0.17
10.8 ±
0.5
12.5 ±
0.29
13.5 ±
0.3
P< ––– H.S H.S H.S ––– H.S H.S H.S
AST Mean ± SD 1.74 ±
0.038
1.91 ±
0.01
2.06 ±
0.30
2.85 ±
0.05
3.44 ±
0.1
3.91 ±
0.13
1.61 ±
0.01
1.76 ±
0.04
1.93 ±
0.1
2.78 ±
0.03
3.19 ±
0.02
3.58 ±
0.13
P< - - – H.S H.S H.S ––– H.S H.S H.S
ALT Mean ± SD 4.69 ±
0.04
4.82 ±
0.05
4.98 ±
0.1
7.73 ±
0.3
7.96 ±
0.57
8.22 ±
0.4
4.59 ±
0.05
4.77 ±
0.13
4.86 ±
0.14
7.53 ±
0.02
7.82 ±
0.02
7.97 ±
0.03
P< ––– H.S H.S H.S - –– H.S H.S H.S
PK Mean ± SD 15.10 ±
3.70
15.21 ±
3.79
15.32 ±
3.81
36.1 ±
10.3
38.4 ±
12.6
42.3 ±
14.7
14.81 ±
3.12
14.97 ±
3.24
15.30 ±
3.51
24.90 ±
4.70
27.0 ±
10.6
30.1 ±
11.34
P< ––– H.S H.S H.S ––– H.S H.S H.S
Activities were expressed as μ moles/mm/g tissue
H.S: Significant difference P <0 .0005
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ondary to the rapid turn-our of adenine nucleotides
during cancer process. On the other hand, as proposed
by Durak et al. [32] high XO activity may be an attempt
to lower salvage pathway activity for purines, which is
vital for rapid DNA synthesis in cancerous bladder tis-
sue. Moreover, Mohamed et al. [33] found a significant
increase in XO activity in mice infected with S. mansoni
parasite.
Given the evidence that supports a relationship
between abnormal glucose metabolism and cancer risk,
serum fructosamine, one of the markers of abnormal
glucose metabolism, is a glycated protein resulting from
spontaneous, non enzymatic condensation of glucose
and proteins, produces an unstable ketoamine, which is
generally referred to as fructosamine due to its struc-
tural similarities to fructose [34,35]. As albumin is the
most abundant protein in serum and contains multiple
Table 4 Essential amino acid fractions in different groups of bladder cancer and bilharzial bladder cancer patients
Parameters Control Bladder cancer Bilharzial bladder cancer % Change
(a) (b) (c)
Isoleucine 2.75 ± 0.390 5.27 ± 1.24 5.3 ± 0.89 +92 +52 +90
Leucine 5.36 ± 0.397 9.73 ± 2.88 9.99 ± 1.82 +81 +29 +86
Threonine 7.70 ± 1.175 9.78 ± 3.30 8.3 ± 2.63 +27 -37 +8
Valine 3.15 ± 0.83 10.28 ± 4.43 11.6 ± 2.32 +226 +51 +267
Phenylalanine 3.12 ± 0.46 5.07 ± 1.07 4.7 ± 0.78 +62 +31 +51
1-Methyl-Histidine 5.22 ± 0.58 7.48 ± 1.167 6.7 ± 2.27 +43 +36 +29
Lysine 8.56 ± 1.43 16.59 ± 3.98 16.9 ± 3.22 +94 +75 +97
Trytophan 1.34 ± 0.39 0.000 ± 0.00 1.5 ± 1.35 -100 -66 +15
Carnosine 2.84 ± 0.58 1.18 ± 0.62 2.1 ± 0.71 -58 -41 -26
Cystathionine 0.923 +0.59 0.153+0.14 0.47 +0.99 -83 -84 -49
￿ Data are means ± S.D. of five patients in each group.
￿ Total amino acid is expressed as g/L serum.
￿ (a, b and c) percentage change as compared with control.
Table 5 Non-essential free amino acid fractions in different groups of bladder cancer and bilharzial bladder cancer
patients
Parameters Control Bladder cancer Bilharzial bladder cancer % Change
(a) (b) (c)
Asparatic acid 2.61 ± 1.07 5.399 ± 2.230 14.141 ± 10.35 +106.78 +29 +442
Proline 4.46 ± 0.24 14.84 ± 5.37 10.227 ± 3.13 +232.5 +177 +129
Glycine 14.14 ± 2.72 9.19 ± 1.22 6.917 ± 4.55 -35 -99.98 -51
Alanine 1.09 ± 0.23 19.75 ± 7.43 14.421 ± 3.34 +1703 +1457 +1216
Serine 7.98 ± 0.81 12.03 ± 3.15 8.977 ± 2.20 +51 +19 +13
Glutamic acid 31.38 ± 3.16 35.32 ± 4.64 44.53 ± 14.03 +13 +33 +42
Tyrosine 4.23 ± 0.35 5.92 ± 1.91 6.455 ± 0.79 +40 +40 +53
NH4+ 4.23 ± 1.16 9.43 ± 1.94 5.955 ± 2.74 +123 +11 +41
Phosphoserin 0.19 ± 0.06 0.24 ± 0.086 0.280 ± 0.21 +27 -1.1 +49
Taurin 3.35 ± 0.49 6.53 ± 1.69 3.075 ± 0.23 +95 -18 -8
Urea 76.5 ± 9.86 88.28 ± 7.24 111.95 ± 9.32 +15 + 5 +46
Cystine 3.22 ± 0.57 3.99 ± 0.81 3.884 ± 1.15 +24 -37 +21
Citrulline 0.96 ± 0.41 1.51 ± 0.36 1.198 ± 0.41 +147 -42 +24
Ornithine 4.396 ± 0.71 11.114 ± 3.42 5.467 ± 0.81 +153 +75 +24
Arginine 3.58 ± 0.71 7.72 ± 1.23 27.3 ± 3.01 +115 +289 +663
a-Aminobutyric acid 0.0197 ± 0.01 0.188 ± 0.32 0.0010 ± 0.001 +854 +28 -95
a-Aminoadipic acid 1.530 ± 0.29 0.0012 ± 0.002 0.282 ± 0.261 -99.9 -100 -82
￿ Data are means ± S.D. of five patients in each group.
￿ Total amino acid is expressed as g/L serum.
￿ (a, b and c) percentage change as compared with control.
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the determination of glycated albumin [36]. This non
enzymatic modification of protein is considered by sev-
eral authors as a possible common mechanism involved
in the progression of many pathological conditions such
as myocardial and renal fibrosis, colorectal adenoma and
chronic renal failure [35,37].
The current investigation revealed that there was a
highly significant increase in fructosamine level in bil-
harzial bladder cancer and non-bilharzial bladder cancer
patients compared to normal ones. This data is in line
with Misciagna et al. [35,38] who reported that fructosa-
mine is associated with colorectal adenoma. Also, Platek
et al. [39] observed a 60% risk increase for breast cancer
in women with high levels of fructosamine, suggesting
that fructosamine, as an indicator of glucose consump-
tion, may be a predictor of breast cancer. Recently,
Pasanisi et al. [40] found that fructosamine was not
associated with recurrence of breast cancer. Mohamed
et al. [33] reported an increase in serum fructosamine of
S. mansoni infected mice, this results was in accordance
with our result in case of bilharzial baldder cancer
patients. Our results are important because this is the
first study investigating serum fructosamine in relation
to bladder cancer and may be used as a useful marker
for bladder carcinoma risk.
Malignant tumors inhabit a complex carbohydrate
metabolism which differs from that of non-neoplastic
cells with two main paradigms: 1) malignant cells pro-
duce large amounts of lactate even in the presence of
sufficient oxygen for aerobic glycolysis. 2) intermediates
of the tricarboxylic acid cycle (TCA) are used for fatty,
amino and nucleic acid synthesis [41,42]. Thus, the
extensive glucose uptake of cancer cells is needed not
only for energy supply but also to provide the compo-
nents for cellular growth and a high amount of reducing
equivalents such as NADPH[41,42]. To accomplish this,
high levels of pyruvate are needed which can be intro-
duced either into the TCA, converted into acetyl-COA
or degraded to lactate by LDH[41-43]. By degradation of
pyruvate to lactate by LDH, the pool of reductive
equivalents on the one hand and the availability of citric
acid cycle intermediates for fatty and amino acid synth-
esis on the other hand is raised. The overexpression of
LDH5 in tumor cells supports this theory of a glucose
metabolism optimized for cellular growth within malig-
nant tumors.
Results in the present study showed a highly signifi-
cant increase in LDH activity in both serum and bladder
carcinoma tissues of bilharzial bladder and non-bilhar-
zial bladder patients compared to healthy ones. The
highest significance was observed in grade III of the dis-
ease. These results are in harmony with Kayser et al.
[44] who found that immunohistochemical analysis for
LDH5 expression in non-small cell lung cancer
(NSCLC) is specific to differentiate malignant neoplasia
from healthy lung tissue. The authors reported that
LDH5 overexpression in cancer cells induces an upregu-
lated glycolytic metabolism and induced dependence on
the presence of oxygen. In addition, Wu et al. [45]
found that the level of LDH was significantly higher in
patients with liver metastasis of colorectal cancer than
those without liver metastasis.
Another glycolytic enzyme was also estimated in the
present study, which is pyruvate kinase enzyme, catalyz-
ing the conversion of phosphoenol pyruvate into pyru-
vate. Our results revealed significant increase in the
activity of PK enzyme in bilharzial and non-bilharzial
bladder tissues when compared to the unaffected normal
ones. In accordance with our data Shonk et al. [46] stu-
died the activities of different glycolytic enzymes in car-
cinoma of rectum and colon and in the corresponding
non-malignant counterparts. They observed that glycoly-
tic enzyme activities of the neoplastic tissues of rectum
and colon are much higher than the activites in the cor-
responding normal rectum and colon. Also, Ramo Rao
[47] stated that the glycolytic enzyme pyruvate kinase
requires potassium for its maximum activity i.e., the
enzyme activity correlates with potassium concentration
in tissues or blood. In support, Reddy et al. [48]
expected that the levels of potassium which may be a
cofactor for pyruvate kinase should be higher in carci-
noma tissues. Recently, Rautray et al. [49] observed that
a potassium level in the carcinoma blood of gallbladder
is lower than those in the normal blood samples. Potas-
sium is a major intracellular cation which is also
excreted in gastrointestinal tract, sativa, gastric juice,
bile, pancreatic and intestinal juices, its deficiency causes
acidosis, renal damage and cardiac arrest.
The metabolism of healthy and functionally active
cells is optimized for productivity in terms of fulfilling
their duty to synthesize, degrade, transport or contract.
In contrast to this, malignant tumor cells do not meet
these demands but only strive for cellular growth and
mitosis [44]. According to this theory high amounts of
ATP as demanded within healthy cells are not only not
required but act contra - productive for the synthesis of
basic elements for cellular growth such as proteins,
nucleic acids and fatty acids. Protein is a critical reser-
voir of metabolic fuel and may become seriously
depleted during tumor growth [50]. The metabolism of
protein and amino acids in cancer patients is closely
linked to glucose metabolism and is regulated by a
number of the same hormones and metabolites [51].
Our findings in the current study showed a slight
increase (P < .025) in total protein concentration in
serum of bilharzial bladder cancerous patients compared
to healthy ones while, there was non-significant decrease
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compared to healthy ones. These results are in harmony
with Lai et al. [50] who found that in cancer patients,
increased hepatic protein synthesis and gluconeogenesis
might lead to a slight decrease in plasma free amino
acids levels and a slight increase in plasma protein
levels. On contrary to our results, Rossi Fancelli et al.
[52] reported that whole - body protein breakdown has
been demonstrated to increase in cancer patients and
correlated with gluconeogenesis in malnourished cancer
patients.
On the other hand, Sauer and Dauchy, [53] found that
fructose - 1, 6 - disphosphatase, the enzyme involved in
the conversion of pyruvate to glucose is elevated in the
liver, suggesting that liver protein is utilized for gluco-
neogenesis in cancer patients. Recently Kojima et al.
[54] detected an elevated proteins in serum of gastric
cancer patients with peritoneal dissemination compared
with serum samples from patients with gastric cancer in
general.
On the contrary of our results, Alexandrakis et al. [55]
found a significant reduction in serum total protein in
malignant neoplasms and cirrhotics. Also, Haitel et al.
[56] stated that transitional cell carcinoma and squa-
mous cell carcinoma of the bladder differ in terms of
protein expression and prognosis. In addition Ali et al.
[57] found a significant reduction in serum total protein
content in bladder cancer, and bilharzial bladder cancer
patients compared to the control healthy group and the
authors recorded that the decrease was more in bilhar-
zial bladder cancer group than the two other groups.
The data obtained in the current study of diagnostic
marker enzymes revealed a marked increase in the activ-
ities of aspartate and alanine aminotransferases in serum
and tissues of bilharzial bladder cancer and non-bilhar-
zial bladder cancer versus healthy controls and the high-
est levels in activities of enzymes were obvious in grade
III of the bladder cancer.
The increased of AST and ATL levels were more spe-
cified extra cellular release and decreased protein con-
tent. Several reports confirmed the elevation in AST
and ALT activities as a result of S.mansoni infection
which may reflect a decrease in hepatic cells, where
Salah et al. [58] and Ahmed [59] indicated the decrease
in hepatic enzymes activities may be due to the release
of the enzymes from the necrotic tissue or due to
increased cell membrane permiability as a result of rela-
tive anoxia and irritation by toxic or metabolic wastes of
the worms.
The extra cellular release of the transaminases leads to
their increase in serum [60], while the reduction of
enzymes activities relative to lower liver protein content
was either due to their release in the bloodstream or due
to their decrease synthesis, since transaminases can serve
as an index of metabolic aerobity degree, and AST can
provide Krebs cycle intermediates, while ALT can be cor-
related with lactate production [61]. The authors also
reported that the elaborated ROS causing damage of cel-
lular membrane, and hence, AST and ALT are sub-cellu-
lar enzymes localized in mitochondria and cytoplasm,
their release to the bloodstream was increased and their
synthesis at the same time decreased.
In accordance with our findings, Ali et al. [57] who
recorded more significant elevation values of AST, ALT
in bilharzial and non bilharzial bladder cancer patients
compared to normal group. Recently, Wu et al. [45]
found that the levels of ALT and AST were significantly
higher in patiens wih liver metastasis of colorectal can-
cer than in those without liver metastasis.
The amino acids can be classified into two major cate-
gories. The essential amino acids are obtained solely
from the diet, whereas the body can, under some cir-
cumstances, produce non-essential amino acids from
other sources. In certain cancers the amino acid profile
yields useful data about the disease from which treat-
ment approaches may be better assessed. Colorectal
cancer patients exhibit a characteristic amino acid pro-
file: significantly lower taurine, glutamine, valine, and
tyrosine in plasma; significantly lower taurine, glutamic
acid, methionine and ornithine intracellularly; and ele-
vated valine, isoleucine, leucine, tyrosine, and phenylala-
nine intracellularly. Obtaining the amino acid profile
may help to construct an appropriate dietary manipula-
tion program aimed at modifying intracellular amino
acid concentration[62]. Likewise, squamous cell carci-
noma of the head and neck exhibit a profile that is
marked by decreased taurine, alanine, asparagine, aspar-
tic acid, glycine, histidine, ornithine, phenylalanine, ser-
ine, and threonine, with a marked increase in levels of
cystine. These features are noted regardless of the stage
of the cancer and nutritional status. Thus, serum amino
acid levels in serum and other tissues may become a
useful cancer marker cancer and provide valuable prog-
nostic information [63].
Remarkable difference in amino acid profiles between
the colorectal cancer patients and the control subjects is
found in this study and most of the differences are sta-
tistically significant in respect of non-essential amino
acids. The difference in essential amino acids concentra-
tion was noticeably insignificant except for methionine
and theronine. Furthermore, some studies showed that
the concentration of amino acids in subjects might be
correlated with the same diseases[64].
The current investigation showed a significant increase
in hydroxyproline level in serum of bilharzial bladder
cancer and non-bilharzial bladder cancer versus control
healthy ones. The increase was more in bilharzial blad-
d e rc a n c e rg r o u pt h a nt h et w oo t h e rg r o u p s .I n
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strated an increased levels of hydroxyproline in breast
cancer. Also, Mohamed et al. [33] reported a marked
increase in the level of liver hydroxyproline in infected
mice versus normal healthy ones. Because collagen is
the main element of extracelleular matrix proteins,
hydroxyproline, is an amino acid characteristic of col-
lagen metabolism, used as a marker to express the
extent of liver fibrosis, as it is the major alteration asso-
ciated with morbidity [66]. Similar result was obtained
by some authors who emphasized that elevated liver
hydroxyproline content was associated with S. mansoni
infection [67,68] and this may be attributed to that S.
mansoni egg granulomas contain factors reposible for
the elevation of free L-hydroxyproline content in the
fibrotic liver [69].
Although IgE is well known for its role in atopic dis-
ease and parasitic infections, new evidence suggests that
IgE is a pleiotropic Ig molecule with many more func-
tions. Previous studies have shown that IgE possesses
antiviral activity, in that IgE anti-HIV-1 antibodies were
able to elicit viral clearance and killing through inhibit-
ing virus production [70].
Data in the present work showed a significant increase
in IgE level in bilharzial and non-bilharzial bladder can-
cer compared to normal group. It is well established
that helminthes infestation induces a very high level of
serum IgE which is present at both the initial and later
stages of schistosomiasis [71]. In western countries
where the incidence of parasitic disease is very low, a
raised IgE may also occur in some patients with cancer
[72].
In accordance with our findings, Ottesen et al. [73]
indicated that IgE is directed mainly against egg antigen
in patients with acute bilharziasis, but it is directed
equally to cercarial, egg and adult worm antigens in
patients with chronic infestation. In addition, Pidcock et
al. [74] reported that the well established increase in IgE
level in patients with schistosomiasis, was also found in
bilharzial bladder cancer, indicating that humeral immu-
nity persists in cancer - bearing patients. Patients with
cancer not associated with parasitic infestation also had
significant increase in their serum level of IgE when
compared to healthy Egyptian controls, but 41% of these
non-bladder cancer patients showed IgE responses to
previous parasitic infestations suggesting that only
immunological response to cancer would be on the
background of a variable non-specific increase of IgE.
IgE was reported to have the major role in mast cells
stimulation which has a central role in the induction of
chronic inflammation [75] and the progression of hepa-
tic fibrosis by producing fibrogenic inflammatory media-
tors as well as the components of the extracellular
matrix proteins (ECMPs) [76,77]. Elevated IgE levels
have been reported in Hodgkin’s lymphoma (HL) and
advanced stage of HL disease has also been found to be
correlated with elevated IgE [78].
It has been postulated that the association between
HL and high serum IgE levels is linked to suppressor
lymphocyte dysfunction (CD8+) and is distinct from the
increase in allergen - specific IgE, which is associated
with atopy [79]. Recently, Fu et al. [80] reported the pre-
sence of elevated IgE and its receptor SCD23 in serum
obtained from pancreatic cancer patients versus con-
trols, whereas other Ig isotypes (IgG, IgM, IgA) did not
differ between patient and control populations. Also,
Chang et al. [81] reported that high maternal IgE levels
were positively associated with childhood leukemia, sug-
gesting that maternal immune function may play a cru-
cial role in the etiology of childhood leukemia.
The current work was also extended to study the
inflammatory cytokine, tumor necrosis factor - alpha
(TNF-a) in bilharzial and non-bilharzial bladder cancer
patients. The data revealed a significant increase in
TNF-a level in bilharzial and non-bilharzial bladder
cancer patients versus normal controls. These results
are in harmony with Wahl and Kleinman, [82] who
found an increase in TNF-a in prostate cancer patients
and they attributed this increase in TNF-a level to the
increase of the inducible nitric oxide synthase (iNOS)
which is one of the major responses of inflammatory
component in a neoplastic transformation. As a result
nitric oxide (NO) species have been implicated not only
in direct damage to cellular components like DNA and
proteins, but can also cause changes to the antioxidant
defense of a cell along with increased ROS and could be
one of the driving factors for promoting prostate cancer
[83]. Therefore, in addition to ROS generated by inflam-
matory cells, uncontrolled tumor cell proliferation in an
environment rich in growth factors, activated stroma
and tumor associated neo-vascualization, can potentiate
and/or promote the development of prostate cancer
[84].
Beside, it was reported that TNF-a essentially func-
tions as a trophic factor for maintaining adult schisto-
some viability, it is expressed during egg deposition and
has a crucial role in the modulation of granulomatous
reaction induced by the eggs [85]. Torben and Hailu
[86] stated that increased level of this inflammatory
cytokine after egg excretion may be an indication of its
effect in complications of schistosomiasis, it capable of
inducing tissue injury and fibrosis through inducing
ROS production, lipid peroxidation [87], collagen synth-
esis other fibrogenic risk factors [88].
In summary, our results add to exicisting evidence by
showing the complexity of the association of bilharzias
and bladder cancer. This association seems to be depen-
dent on the repeated infestion of the bladder with S.
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of the studied biochemical parameters among bilharzial
and non bilharzial bladder cancer and normal control
subjects. This work is believed to highlight the essential
biochemical markers that can be important candidates
for bladder cancer diagnosis. In this study, we found
that serum fructosamine, as an indicator of glucose con-
sumption, may be a predictor of bladder cancer, also the
amino acid, hydroxylproline, as an indicator of liver
fibrosis, may be a predictor of bladder cancer risk, in
addition, IgE and TNF-a are also may be used as a new
immunological markers of bladder cancer.
Conclusion
As a conclusion, increased of all previously mentioned
markers in both serum and tissues of patients might be
a potentially important findings as an additional diag-
nostic biochemical tools for bladder cancer.
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